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Type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer disease (AD). Previous studies 
have shown that the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP) that have anti-diabetic properties show very 
promising effects in animal models of AD. Glucagon (Gcg) is a hormone and growth-factor, 
and the Gcg receptor is expressed in the brain. Here we test the effects of a triple receptor 
agonist (TA), which activates GIP-1, GIP and glucagon receptors at the same time. In the 
present study, the effects of the TA were evaluated in the APP/PS1 transgenic mouse model of 
AD. The TA was injected once-daily (10 nmol/kg i.p.) for two months. The results showed 
that treatment with TA significantly reversed the memory deficit in the APP/PS1 mice in a 
spatial water maze test. Moreover, the drug reduced levels of the mitochondrial pro-apoptotic 
signaling molecule BAX, increased the anti-apoptotic signaling molecule Bcl-2 and enhanced 
the levels of BDNF, a key growth factor that protects synaptic function. Levels of 
synaptophysin were enhanced, demonstrating protection from synaptic loss that is observed in 
AD. Neurogenesis in the dentate gyrus was furthermore enhanced as shown in the increase of 
doublecortin positive cells. Furthermore, TA treatment reduced the total amount of ß-amyloid, 
reduced neuroinflammation (activated microglia and astrocytes), and oxidative stress in the 
cortex and hippocampus. Thus, these findings show that novel TAs are a promising lead for 
the design of future treatment strategies in AD. 
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Alzheimer’s disease (AD), is a progressive neurodegenerative disease, characterized 
clinically by progressive memory loss, cognitive decline, and aberrant behavior [1].  
Currently, there is no treatment can improve this condition. Epidemiological studies have 
shown that type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer disease (AD) 
(Luchsinger et al., 2004; Ohara et al., 2011). The underlying mechanism is most likely that 
insulin signaling is impaired in the brains of AD patients (Moloney et al., 2010; Talbot et al., 
2012). This motivated research in drugs that have shown good effects in treating diabetes to 
investigate if they could be helpful in treating AD as well. Previous studies have shown that 
the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP) can play a neuroprotective role in the brain and show very promising 
effects in animal models of AD (Duffy and Holscher, 2013; Faivre and Holscher, 2013b; Li et 
al., 2010; McClean et al., 2011; McClean and Holscher, 2014). Glucagon (Gcg) is a hormone 
and growth-factor, and the Gcg receptor is expressed in the brain (Hoosein and Gurd, 1984; 
Mayo et al., 2003). Activation of the receptor can activate neuronal activity and cellular Ca2+ 
signalling and may have neuroprotective properties (Ayush et al., 2015). Here we test the 
effects of a triple receptor agonist (TA), which activates GIP-1, GIP and glucagon receptors at 
the same time. This novel drug has been developed as a potential treatment for diabetes 
(Finan et al., 2015). No studies have been published that test the neuroprotective effects of 
this novel drug. We therefore tested this promising TA in the APPSWE/PS1dE9 mouse model of 
AD. This mouse model recapitulates some of the hallmarks of AD, such as memory loss, 
synaptic loss, reduction of synaptic plasticity, reduction of neurogenesis in the dentate gyrus, 
chronic inflammation in the brain, and formation of amyloid plaques in the brain (Duffy and 
Holscher, 2013; Goto et al., 2008; Hamilton et al., 2011; Hamilton and Holscher, 2012; 
McClean et al., 2011). We tested the effects of TA in this transgenic mouse model and 
evaluated the neuroprotective effects. We analysed memory formation, hippocampal 
neurogenesis, the expression levels of Brain Derived Neurotrophic Factor (BDNF) (Blurton-
Jones et al., 2009), mitochondrial apoptosis signaling proteins, neuroinflammation and 




2.1 TA-treatment improved the learning and memory impairment of APP/PS1 mice in the 
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water maze. 
A two-way ANOVA found a significant difference between groups (p<0.0001) and over 
time (p<0.001). In the Morris water test, it was observed that the control mice, APP/PS1 mice 
and TA-treated APP/PS1 mice had a similar escape latency (P>0.05). On day 5, the average 
escape distance in searching for the hidden platform in the APP/PS1 mice was significantly 
longer than that in the control mice (P<0.05). Compared to the APP/PS1 group, the TA-
treated APP/PS1 group’s average escape distance was decreased (P<0.01). There was no 
difference in swimming speed among these three groups in training days (P>0.05). 
Then on day 6, the platform was removed and the probe trail test was conducted. A one 
way ANOVA analysis showed an overall difference between groups. The APP/PS1 mice spent 
less time in the target quadrant (P<0.01) and had fewer times passing through the original 
position of the hidden platform (P<0.01), compared with control mice. In the TA-treated 
APP/PS1group, the time spent in target quadrant (P<0.05) and the frequencies to cross the 
platform significantly increased (P<0.05), compared to the APP/PS1 group. 
 
2.2 TA-treatment ameliorated amyloid plaques in the brains of APP/PS1 mice. 
In the immunohistochemical analysis, we analyzed the amount of amyloid plaques present 
in the brains of APP-PS1 mice. A one-way ANOVA found an overall difference on the 
amyloid deposits in the cortex (F=31.10, P＜0.0001) and the hippocampus (F=30.38, P＜
0.0001) of mice between groups. The Aβ1-42 depositions in the cortex and hippocampus of the 
APP/PS1 mice were significantly higher than that in the control mice (P＜0.001), while TA-
treatment group significantly decreased the deposition (P＜0.001) compared to the APP/PS1 
group. N=6 per group. See Fig.2.  
 
2.3 TA-treatment reduced the chronic inflammation response in the cortex and hippocampus 
of the APP/PS1 mice	
In the immunohistochemical analysis, an anti-GFAP antibody was used as an indication of 
activated astrocytes. A one-way ANOVA found an overall difference on the GFAP expression 
in the cortex (F=77.03, P＜0.0001) and the hippocampus (F=86.51, P＜0.0001) of mice 
between groups. The levels of GFAP in the cortex and hippocampus of the APP/PS1 mice 
were significantly higher than that in the control mice (P＜0.001), while TA-treatment group 
significantly decreased (P＜0.001) compared to the APP/PS1 group. N=6 per group. See Fig. 
3. 
a triple receptor agonist is neuroprotective	
	 5	
In the immunohistochemical analysis, an anti-IBA1 antibody was used as an indication of 
microglia activation. A one-way ANOVA found an overall difference on the IBA-1 expression 
in the cortex (F=28.71, P＜0.0001) and the hippocampus (F=66.42, P＜0.0001) of mice 
between groups. The levels of IBA-1 in the cortex and hippocampus of the APP/PS1 mice 
were significantly higher than that in the control mice (P＜0.001), while TA-treatment group 
significantly decreased (P＜0.001, P＜0.01) compared to the APP/PS1 group. N=6 per group. 
See Fig. 4. 
 
2.4 TA-treatment suppressed oxidative stress in the cortex and hippocampus of APP /PS1 
mice. 
In the immunohistochemical analysis, 4-HNE was measured as an indicator of lipid 
peroxidation. A one-way ANOVA found an overall difference on the 4-HNE expression in the 
cortex (F=60.60, P＜0.0001) and the hippocampus (F=35.22, P＜0.0001) of mice between 
groups. The expressions of 4-HNE in the cortex and hippocampus of the APP/PS1 mice were 
significantly higher than that in the control mice (P＜0.001), while TA-treatment group 
significantly decreased (P＜0.001) compared to the APP/PS1 group. N=6 per group, see Fig. 
5a. 
In the immunohistochemical analysis, 8-OHdGwas measured as an indicator of DNA 
oxidation. A one-way ANOVN found an overall difference on the 8-OHdG expression in the 
cortex (F=38.72, P＜0.0001) and the hippocampus (F=56.60, P＜0.0001) of mice between 
groups. The expressions of 8-OHdG in the cortex and hippocampus of the APP/PS1 mice 
were significantly higher than that in the control mice (P＜0.001), while TA-treatment group 
significantly decreased (P＜0.01, P＜0.001) compared to the APP/PS1 group. N=6 per group, 
see Fig. 5b. 
 
2.5 TA-treatment increased immature neurons in the dentate gyrus of APP/PS1 mice.  
In the immunohistochemical analysis, numbers of neurogenesis, assessed by doublecortin 
(DCX). A one-way ANOVN found an overall difference on the DCX positive cell in the 
dentate gyrus (F=43.61, P＜0.0001) of mice between groups. The numbers of DCX were 
much reduced in the APP/PS1 mice (P＜0.001) compared to the control mice. While TA-
treatment partially prevented the reduction (P＜0.001) compared to the APP/PS1 mice. N=6 
per group. See Fig. 6. 
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2.6 TA-treatment reversed the decrease of BDNF levels in the hippocampus of APP/PS1 mice. 
BDNF, a key neurotrophic factor in the brain, was detected by Western blot analysis. A one-
way ANOVA found an overall difference between groups (F=20.01, P＜0.001). The 
expression of BDNF in hippocampus was reduced in APP/PS1 group (P＜0.001) compared to 
the control group. TA-treatment reversed the decreased (P＜0.05) compared to the APP/PS1 
group. N=6 per group. See Fig. 7a. 
 
2.7 TA-treatment reversed the reduction of synaptophysin levels. 
Synaptophysin (SYN), a synaptic markers, was detected by Western blot analysis. A one-
way ANOVA found an overall difference between groups (F=20.46, P＜0.001). The level of 
SYN in hippocampus was decreased in the APP/PS1 group (P＜0.001) compared to the 
control group. While TA-treatment prevent the reduction (P＜0.01) compared to the APP/PS1 
group. N=6 per group. See Fig.7b. 
 
2.8 TA-treatment showed potential anti-apoptotic effects by decreasing the BAX/Bcl-2 ratio 
in APP/PS1 mice. 
The expression of apoptotic proteins, including Bcl-2 (that suppress apoptosis) and BAX 
(that promotes apoptosis), was detected by Western blot analysis. A one-way ANOVA found 
an overall difference between groups (F=77.64, P＜0.001). The ratio of BAX/Bcl-2 in 
hippocampus was increased (P＜0.001) compared to the control group. While TA-treatment 
partly decreased the ratio of BAX/Bcl-2 (P<0.001) compared to the APP/PS1 group. N=6 per 





The results demonstrate for the first time that the novel GLP-1/GIP/Gcg receptor agonist has 
clear neuroprotective effects in the APP/PS1 mouse model of AD. Memory formation in the 
spatial water maze task was improved by the drug, and the amyloid plaque load in the cortex 
and hippocampus was reduced. This result confirms our previous findings that single GLP-1 
or GIP analogues can protect from memory loss in this mouse model of AD (Faivre and 
Holscher, 2013a; Faivre and Holscher, 2013b; McClean et al., 2011; McClean and Holscher, 
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2014). The chronic inflammation response as seen in the activation of microglia and 
astrocytes is much reduced by the novel TA, similar to single GLP-1 or GIP receptor agonists 
(Duffy and Holscher, 2013; Ji et al., 2016a; McClean et al., 2011). Levels of the peroxidized 
lipid 4-HNE that also acts as a pro-apoptotic signal in mitochondria have been reduced by the 
TA. 4-HNE is one of the markers of membrane lipid peroxidation induced by cytotoxic 
radicals such as •OH. 4-HNE has cytotoxic, mutagenic and genotoxic properties and 4-HNE 
is reported to stimulate apoptosis via caspase 3 activation and by inducing mitochondrial 
damage as shown in cytochrome c release (Ji et al., 2001). The levels of the mitochondrial 
apoptosis signal BAX (Kim et al., 2005) were also reduced. Importantly, the anti-apoptotic 
signaling molecule B-cell lymphoma 2 (Bcl-2) which is active in functioning mitochondria 
that have normal inner membrane voltage potentials (Kavitha et al., 2013) is upregulated by 
the TA, adding to the neuroprotective effect. The level of chronic oxidative stress as measure 
by the levels of the oxidized nucleotide 8-Hydroxiguanosine (8-OHdG) was also reduced by 
the drug. Neurogenesis in the dentate gyrus was normalized. Importantly, the levels of the key 
growth factor BDNF were normalized in the brain. BDNF has shown clear neuroprotective 
effects in a range of animal models of disease (Allen et al., 2013; Benedetti et al., 2014; 
Blurton-Jones et al., 2009; Nagahara et al., 2013). An important factor of BNDF activity is 
that it maintains synaptic activity and protects synapses from stressors (Kuipers and 
Bramham, 2006). The observation that the synaptic marker synaptophysin was expressed at 
normal levels after TA treatment also indicates that synaptic numbers and function was 
improved in the AD mouse. We have shown previously that GLP-1 and GIP analogues protect 
synapses from amyloid induced stress and keeps them functional (Faivre and Holscher, 
2013b; Gault and Holscher, 2008a; Gault and Holscher, 2008b; McClean and Holscher, 2014). 
Recently, multiple receptor agonists have been developed to treat type II diabetes (Finan et al., 
2013; Finan et al., 2015). We have tested novel dual GLP-1/GIP receptor agonists that showed 
good neuroprotective effects that are superior to single GLP-1 analogues (Cao et al., 2016; 
Jalewa et al., 2017; Ji et al., 2016b; Yuan et al., 2017). The novel dual agonist DA3-CH was 
found to be superior to liraglutide in a mouse model of Parkinson’s disease (Yuan et al., 
2017), demonstrating that the strategy of activating more than one incretin receptor type 
offers an advantage over single receptor agonists. Here, we show that a novel triple receptor 
agonist also shows promise as a potential treatment for AD, but further dose-response tests 
and direct comparisons with other drugs have to be conducted in order to evaluate the if this 
new drug is superior to previous ones. 
GLP-1, GIP and glucagon are members of the growth factor family (Hölscher, 2016). Their 
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respective receptors are classic 7-membrane spanning domain, G-protein coupled receptors 
that activate cAMP synthesis(Campbell and Drucker, 2013; Doyle and Egan, 2007; Holst et 
al., 2011). The activation of the second messenger cascade cAMP-PKA-CREB induces a 
number of cytoprotective processes, including the normalization of energy utilization, cell 
repair and growth-factor related gene expression (Holscher, 2014; Jalewa et al., 2016; Perry 
and Greig, 2004; Sharma et al., 2013). Importantly, GLP-1 and GIP also have anti-
inflammatory properties. Astroglia and microglia express the receptors, and activating these 
reduce the inflammation response (Duffy and Holscher, 2013; Jalewa et al., 2017; 
Parthsarathy and Holscher, 2013; Spielman et al., 2017). Chronic inflammation is a main 
driver of neurodegenerative disorders, and a reduction of the inflammation in the brain shows 
protective effects (Akiyama et al., 2000; Clark et al., 2012; Lee et al., 2010).   
Based on the impressive preclinical data that demonstrate neuroprotection of such drugs, 
clinical trials have started that investigate the neuroprotective effects of the GLP-1 receptor 
agonists exendin-4 (Byetta, Bydureon®) and liraglutide (Victoza®) in patients with AD or 
with Parkinson disease (PD). A pilot study testing the GLP-1 analogue liraglutide in AD 
patients showed promising results. In a double blind, placebo controlled trial, AD patients 
showed no deterioration in brain activity as measured in the 18FDG-PET scan after 12 months 
of drug treatment. In contrast, the placebo group showed clear reductions in cortical activity 
as expected for this progressive neurodegenerative disease (Gejl et al., 2016). A phase II 
clinical trial is currently ongoing (Hölscher, 2016). A pilot trial testing exendin-4 in PD 
patients has shown good effects (NCT01174810). This open-label study tested the effects of 
exendin-4 in 45 patients. There were clear improvements in the motor coordination as shown 
in the MDS-UPDRS part 3 assessment, and cognition was improved as measured by the 
Mattis DRS-2 test battery that had been designed to evaluate cognitive impairments in PD 
patients (Aviles-Olmos et al., 2013). Patients were re-tested 12 months later, and the 
differences in motor performance and cognitive scores were still visible (Aviles-Olmos et al., 
2014). A phase II double-blind, placebo controlled clinical trial that tested the once-weekly 
formulation of exendin-4, Bydureon®, confirmed the results of the pilot study. The drug 
group did not deteriorate in the MDS-UPDRS part 3 assessment after 48 weeks of treatment, 
and after 12 weeks of a wash-out period, the disease-modifying effect was still visible. In 
contrast, the placebo group deteriorated over time as would be expected in this disease 
(Athauda et al., 2017). In addition, a phase II trial testing liraglutide in PD patients has 
started, testing patients in a double blind, placebo controlled trial for one year 
(NCT02953665). A further clinical trial testing the GLP-1 receptor agonist Lixisenatide in PD 
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patients is in planning. 
These very promising preclinical and the first clinical outcomes demonstrate the efficacy of 
these novel multiple receptor agonists that originally were developed to treat type II diabetes, 
but have shown consistent neuroprotective effects in several studies. In the present study, the 
novel TA improved learning and memory, reduce amyloid plaque load, chronic inflammation 
and oxidative stress, as well as mitochondrial stress signalling, and improved BDNF release 
and synaptic markers while normalising neurogenesis in the dentate gyrus. The novel triple 
GLP-1/GIP/Gcg receptor agonist holds clear promise of being developed into a new treatment 
for chronic neurodegenerative disorders such as Alzheimer’s disease. 
 
 
4. Materials and methods 
4.1 Peptide and chemicals 
The triple GLP-1/GIP/Gcg used in this study was synthesized by China Peptides Co, Ltd. 
(Shanghai, China) to 95% purity. The identity and purity of the peptide was confirmed by 
reversed-phase HPLC and characterized using matrix assisted laser resorption/ionization time 
of flight (MALDI–TOF) mass spectrometry. The peptide was stored in dry form and dissolved 
in double-distilled water containing 0.9% NaCl2 before experiments. A Bi-cinchoninicacid 
(BCA) protein assay kit was purchased from Apply gen Technologies Inc. (Beijing, China). 3, 
3-diaminobenzidine (DAB) was purchased from ZSGB-BIO Co. (Beijing, China). The 
primary antibodies recognizingAβ1-42, IBA-1, BDNF, 4-Hydroxynonenal (4-HNE), 8-
Hydroxyguanosine (8-OHdG), synaptophysin (SYN) and β-actin were obtained from Abcam 
(Cambridge, UK). The primary antibody GFAP, Bcl-2, and BAX were obtained from Boster 
Biotechnology (Wuhan, China). The primary antibody doublecortin (DCX) buy from Santa 
Cruz Biotechnology. HRP-labeled goat anti-rabbit immunoglobulin was obtained from Abcam 
(Cambridge, UK). The biotinylated goat anti-rabbit IgG, biotinylated rabbit anti-goat IgG, 
avidinbiotin peroxidase complex reagent was purchased from Boster Biotechnology (Wuhan, 
China). All other reagents used in the research were of analytical grade and of the highest 
quality commercially available. The peptide sequence was as follows (Finan et al., 2015): 
HXQGTFTSDKSKYLDERAAQDFVQWLLDGGPSSGAPPPS 
X=aminoisobutyric acid, K = γE-C16 acylation   (with a C16 fatty acid) 
 
 
4.2 Animals and treatments 
APP/PS1 transgenic mice were purchased from the Academy of Military Medical Sciences 
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(AMMS, China), were maintained in a constant temperature (22±1℃) and humidity (relative 
30%) under a 12 h light/dark cycle in animal house. As well as age-matched non-AD mice, 
which are wild-type animals as control. When animals were 6 months of age, TA was 
dissolved in saline. The dose was a once- daily injection of 10nmol/kg body weight ip. for 
two months. Injections were given in the morning (8:00 am). Control mice received equal 
volumes of saline solution. All experimental procedures involving animals were approved by 
the Institutional Animal Care Committee of Shanxi Medical University and conform to the 
guidelines of National Institute of Health (NIH) guideline (NIH publication NO. 85-23. 
Revised 1985). They were divided into three different groups (n = 12). (i): control group 
treated with saline only; (ii): APP/PS1 group treated with saline only; (iii): APP/PS1 group 
treated with TA. At the end of drug treatments, measurements of behavioral change, neuronal 
damage, oxidative stress and inflammatory markers were conducted. 
	
 
4.3 Morris water maze test 
The water maze test (WMM test) is a standard method for assessing learning and memory in 
animals (Morris, 1984) [7]. The water maze (WM) task was performed 5 days after two 
months intraperitoneal injection. The apparatus was a circular, white painted pool (150cm in 
diameter and 60cm in height) which was filled to a depth of 40 cm with warm water at a 
temperature 23± 2˚C to avoid hypothermia, and was surrounded by a white curtain around the 
pool. The pool was divided into four quadrants with four starting locations, north (N), east 
(E), south (S) and west (W), the starting quadrant was randomly chosen. A perspex platform 
(diameter, 10 cm) was located in a specific location during the acquisition trials and 
submerged approximately 1.0 cm below the surface of the water. A video camera was 
mounted directly above the pool to record the movement and the trail of the mice. During the 
acquisition phase, each mouse was subjected to four consecutive training trials on each day. 
The mouse was gently placed in the water between the quadrants, and allowed 60s to search 
the hidden platform. If it failed to find the platform within 60s, it was guided to the platform 
and allowed to remain there for 10s. Training continued for 5 days. On the sixth day, the 
hidden platform was removed and each mouse was allowed to swim in the pool for 60s. The 
mean time spent in all four quadrants and the target area for searching the hidden platform 
was recorded. 
 
4.4 Brain tissue preparation 
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Half of the animals were decapitated after anesthetization with ethyl carbamate, 
hippocampus tissues were immediately isolated and stored at -80℃ for further investigations. 
The second half of each group was used for immunohistochemistry analysis. Animals were 
perfused intracardially with saline and cold 4% paraformaldehyde. Brains were removed and 
post-fixed in 4% paraformaldehyde for 24 h.   
 
4.5 Immunohistochemistry 
For DAB staining, fixed tissues were embedded in paraffin. Coronal sections (5 µm thick) 
of the brains were cut on a Leica microtome for immunohistochemistry. Paraffin was removed 
from the tissue sections with xylene, and the sections were rehydrated in graded ethanol 
solutions. Endogenous peroxidase activity was blocked with 3% H2O2 for 10 min at room 
temperature. Antigen retrieval was performed by heating in 10 mmol/L citrate buffer (pH 6.0) 
for 10 min. After blocked with5% BSA, sections were incubated with the primary antibody 
for doublecortin (goat anti-DCX; 1:50), GFAP (rabbit anti-GFAP; 1:100), IBA-1 (goat anti-
IBA1; 1:200), 4-Hydroxynonenal antibody (goat anti-4 HNE; 1:200) and anti-8 
Hydroxyguanosine antibody (goat anti-8 OHdG; 1:200) at 37˚C for 2h. For the Anti-8 OHdG 
histology, enzymatic antigen retrieval with 10µm/ml proteinase K for 40 minutes at 37˚C was 
performed. To detect amyloid deposits, the primary antibody was Aβ1-42 (rabbit anti-Aβ1-42; 
1:100), brain sections were pre-incubated with 70% formic acid and incubated at 4˚C for 24h. 
They were rinsed in PBS and incubated with biotinylated goat anti-rabbit IgG or biotinylated 
rabbit anti-goat IgG at 37˚C for 0.5h and incubated with the avidin-biotin peroxidase complex 
reagent at 37˚Cfor 0.5h. Samples were stained in DAB solution in the presence of H2O2. All 
stained sections were viewed and photographed under a Zeiss light microscope, and images 
were captured by Motic Images Plus2.0ML software. The numbers of DCX positive neurons, 
the areas of Aβ1-42, GFAP, IBA-1, 4-HNE and 8-OHdG positive cells were determined using 
Image-pro plus6.0 software. The software counts objects that are defined in size and staining 
threshold by the user. This automated process avoided user bias. 
 
4.6 Western blot 
The hippocampal tissues from mice was homogenized in ice cold RIPA buffer (containing 
1% Triton X-100, 0.1% SDS, 1% deoxycholate) and PMSF(phenyl-methylsulfonyl 
fluoride).The homogenate was centrifuged 12,000 rpm/min for 5 min at 4 °C before taking the 
supernatant. Tissue containing 60ug of protein was separated on 10–12% gradient Bis–Tris 
gel with molecular marker and electrophoresed in running buffer at 120 mV for90 min 
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followed by transfer to the PVDF membrane. Following protein transfer, the membrane was 
washed in TBST (trisbuffered saline with 0.05% Tween-20, pH 8) and blocked in 5% skim 
milk for 1 h. Then incubated overnight at 4  with rabbit anti-synaptophysin (SYN) 
(1:10000), rabbit anti-Bcl-2 (1:400), rabbit anti-BAX (1:400), rabbit anti-BDNF (1:5000), 
after three washes in TBS further incubation for2 h at room temperature with the HRP-labeled 
goat anti-rabbit immunoglobnulin (1:5000). In some cases, the blots were stripped and 
reprobed with a rabbit anti-β-actin (1:5000) to ensure equal sample loading. The bound 
antibodies were then visualized by ECL-enhanced chemilluminescence (Beyotime Institute of 
Biotechnology, Shanghai, China) according to the manufacturer's instructions. Western blot 
images were captured with a chemiluminescent imaging system (Sagecreation, Beijing, 
China). All bands were quantified using the image system of Alpha View SA. 
 
4.7 Statistical analysis 
The data were presented as the mean ± standard error of mean (S.E.M) and analyzed by 
one-way or two way ANOVA followed by Bonferroni’s multiple comparison test using the 
software Prism 5 (Graph Pad Software Inc, La Jolla, CA, USA). Statistical significance is 
defined as P<0.05. 
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Fig 1. The novel TA improved the learning ability of APP/PS1 mice in the spatial water maze 
task. (A) The escape latency and swimming speed in the training trails. (B) The percentage of 
time in target quadrant and crossing platform times in the probe trials. The circle indicates the 
position of the platform during acquisition (C) Representative swimming tracks of the probe 
trial.  *=P<0.05, **=P<0.01 compared to the control group, ##=P<0.01, #=P<0.05 compared 
to the APP/PS1 group; Two-way ANOVA with Bonferroni repeated measures post-hoc tests. 
 
Fig. 2. TA treatment reduced amyloid deposits in the cortex and hippocampus of APP/PS1 
mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA group. Scale bar in 
image D: 100µm.  ***=P<0.001 compared to the control group; ###=P<0.001 compared to 
the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post-hoc tests. N=6 
per group. 
 
Fig. 3. TA-treatment reduced the number of GFAP positive cells in the cortex and hippocampus 
of APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA. Scale bar in 
image D: 50µm. A higher magnification image has been added to show stained astroglia. 
***=P<0.001 compared with the control group; ###=P<0.001 compared with the APP/PS1 
group. One-way ANOVA with Bonferroni repeated measures post-hoc tests. N=6 per group. 
 
Fig. 4: TA treatment reversed the increase of IBA-1 positive cells in the cortex and hippocampus 
of APP/PS1 mice. A, D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA group. Scale 
bar in image D: 100µm. A higher magnification image has been added to show stained 
microglia.  ***=P<0.001 compared to the control group; ##=P<0.01, ###=P<0.001 compared 
to the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post-hoc tests. 
N=6 per group. 
 
Fig. 5. Oxidative stress was reduced by the TA. 5A. TA-treatment reduced the increase of 4-
HNE levels in the cortex and hippocampus in APP/PS1 mice. A, D: control group; B, E: 
APP/PS1 group; C, F: APP/PS1+TA group. Scale bar in image D: 100µm. ***=P<0.001 
compared with controls; ###=P<0.001 compared to the APP/PS1 group. Fig.4b.TA treatment 
reduced the increase of 8-OHdG levels in the cortex and hippocampus of APP/PS1 mice. A, 
D: control group; B, E: APP/PS1 group; C, F: APP/PS1+TA group. Scale bar in image D: 
100µm. ***=P<0.001 compared to the control group; ##=P<0.01, ###=P<0.001 compared 
with the APP/PS1 group. One-way ANOVA with Bonferroni repeated measures post-hoc tests. 
N=6 per group. 
 
Fig. 6. TA-treatment enhanced neurogenesis and increased numbers of DCX positive cell 
numbers in the dentate gyrus of APP/PS1 mice. A: control group; B: APP/PS1 group; C: 
APP/PS1+TA group. Scale bar in image A: 100µm.  ***=P<0.001 compared with the control 
group; ###=P<0.001 compared with the APP/PS1 group. One-way ANOVA with Bonferroni 
repeated measures post-hoc tests. N=6 per group. 
 
Fig. 7. A) TA-treatment increased levels of BDNF in the hippocampus of APP/PS1 mice.  
***=P<0.001compared with the control group; #P<0.05 compared with the APP/PS1 group. 
N=6 per group. 
B) TA-treatment increased levels of synaptophysin in the hippocampus of APP/PS1 mice.  
***=P<0.001 compared with the control group; ##=P<0.01 compared with the APP/PS1 
group. N=6 per group. 
C) TA-treatment increased the ratio of BAX/Bcl-2 in the hippocampus of APP/PS1 mice.  
***=P<0.001 compared with the control group; ###=P<0.001 compared with the APP/PS1 
a triple receptor agonist is neuroprotective	
	 17	


















































a triple receptor agonist is neuroprotective	
	 23	
 
Fig. 7 
